Analysis of Pipeline Drugs for Neurodegenerative Disorders Presented in New Report

Published Date : May 02, 2017

ALBANY, New York, May 2, 2017: has announced the addition of a new report, titled “Neurodegenerative Disorders Drug Development Pipeline Review, 2017,” to its expanding repository of research reports. The report is a high-level reports of the various factors that are expected to have a bearing on drug development pipeline for neurodegenerative disorders in the coming years. This includes budget for clinical trials, product development, and expert personnel for research and development. The reports is presented after an extensive research phase and insightful inputs received from industry experts.

Neurodegenerative disorders refer to a group of conditions that affect the central nervous system. Included are hereditary as well as sporadic conditions that are featured by slow, irreversible, and progressive dysfunction of the nervous system. It leads to degeneration of neurons with symptoms such as memory loss, motor impairment, and declining cognitive ability.

The scope of the report is useful from economic as well as research considerations. The reports presented in the report is a useful tool for various entities involved in drug development for neurodegenerative disorders. The report looks into the current status of pipeline drugs of most active companies and where they are headed to attain objectives that are aimed for the coming years. It also looks if academic institutions and research organization have any role in the development of these drugs.

For Sample Copy, click here:

At present, there are more than 1,400 active products under development for degenerative disorders. It includes a number of biologics and small molecules along with gene therapies and cell therapies that demonstrates the broad scope of research and development associated with pipeline drugs.

The report identifies key companies that have active pipeline drugs for Alzheimer’s disease. These include AB Science SA, ac Immune SA, Acelot Inc., Acumen Pharmaceuticals Inc., Affibody AB, Alector LLC, Allergan Plc, Allinky Biopharma, Alzhyme Pty Ltd., AlzProtect, Amgen Inc., Aphios Corporation, Archer Pharmaceuticals Inc., Artery Therapeutics Inc., Astellas Pharma Inc., Asubio Pharma Co. Ltd., Avineuro Pharmaceuticals Inc., Axovant Sciences Ltd., Beactica AB, BioArctic Neuroscience AB, Biogen Inc., Bionature E.A. Ltd., Bristol-Myers Squibb Company, Cardax Pharmaceuticals Inc., Celon Pharma Sp. Z.o.o., Chase Pharmaceuticals Corporation, Cognition Therapeutics Inc., CohBar Inc., ContraVir Pharmaceuticals Inc., Coronis Partners Ltd., Critical Outcome Technologies Inc., D-Pharm Ltd., Daiichi Sankyo Company Limited, Dongkook Pharmaceutical Co. Ltd., Eli Lilly and Company, EncephRx Inc., ENKAM Pharmaceuticals A/S, Ensol BioScience Inc., Euroscreen S.A., F.Hoffmann-La Roche Ltd, Genetech Inc., GlaxoSmithKline Plc, Glialogix Inc., Golden Biotechnology Corp., H. Lundbeck A/S, HitGen LTD., Ichor Medical Systems Inc., Immungenetics AG, ImStar Therapeutics Inc., IntelGenx Corp., Intra-Cellular Therapies Inc., INVENT Pharmaceuticals Inc., Iproteos S.L., Jiangsu Kanion Pharmaceutical Co. Ltd., K-Stemcell Co. Ltd., Kalgene Pharmaceuticals Inc., KineMed Inc., Kyowa Hakko Kirin Co. Ltd., Les Laboratories Servier SAS, Living Cell Technologies Limited, M3 Biotechnology Inc., MedDay SA, MedImmune LLC, MedRx Co. Ltd., Metabolic Solutins Development Company LLC

To order report Call Toll Free: 866-997-4948 or send an email on